You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Colorcon
Boehringer Ingelheim
Dow
McKesson

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ketanserin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ketanserin?

Ketanserin is an investigational drug.

There have been 8 clinical trials for Ketanserin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Renal Insufficiency, Acute Kidney Injury, and Ulcer. The leading clinical trial sponsors are Gitte Moos Knudsen, Medical Centre Leeuwarden, and University Hospital, Basel, Switzerland.

There is one US patent protecting this investigational drug and eleven international patents.

Recent Clinical Trials for Ketanserin
TitleSponsorPhase
Effect of Ketanserin After LSD AdministrationUniversity Hospital, Basel, SwitzerlandPhase 1
Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)Matthias LiechtiEarly Phase 1
The Neurobiological Effect of 5-HT2AR ModulationGitte Moos KnudsenPhase 1

See all Ketanserin clinical trials

Clinical Trial Summary for Ketanserin

Top disease conditions for Ketanserin
Top clinical trial sponsors for Ketanserin

See all Ketanserin clinical trials

US Patents for Ketanserin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ketanserin   Start Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH)   Start Trial
Ketanserin   Start Trial Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent Johnson & Johnson Consumer Inc. (Skillman, NJ)   Start Trial
Ketanserin   Start Trial Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases ACADIA PHARMACEUTICALS INC. (San Diego, CA)   Start Trial
Ketanserin   Start Trial Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH)   Start Trial
Ketanserin   Start Trial Methods and systems for manufacturing a tablet Massachusetts Insititute of Technology (Cambridge, MA)   Start Trial
Ketanserin   Start Trial Pyrimidines as sodium channel blockers Purdue Pharma L.P. (Stamford, CT)   Start Trial
Ketanserin   Start Trial Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC (Newbury Park, CA) SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ketanserin

Drugname Country Document Number Estimated Expiration Related US Patent
Ketanserin Argentina AR104982 2035-06-12   Start Trial
Ketanserin Australia AU2016276966 2035-06-12   Start Trial
Ketanserin Canada CA2989343 2035-06-12   Start Trial
Ketanserin China CN109562085 2035-06-12   Start Trial
Ketanserin European Patent Office EP3307260 2035-06-12   Start Trial
Ketanserin Hong Kong HK1245660 2035-06-12   Start Trial
Ketanserin Israel IL256231 2035-06-12   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Colorcon
Boehringer Ingelheim
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.